SynthesiseLife2022
The clinical pharmacology of tafenoquine in the radical cure of
Abstract readMeta-Analysis
In one paragraph
Synthesis in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis.Malaria journal · 2025Pooled it
- Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.PLoS medicine · 2024Pooled it
- The lymphatic filariasis treatment study landscape: A systematic review of study characteristics and the case for an individual participant data platform.PLoS neglected tropical diseases · 2024Pooled it
- Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.The Lancet. Infectious diseases · 2026Trial
- Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.The Lancet. Infectious diseases · 2023Trial
- Health-care provider compliance with a revisedLancet regional health. Americas · 2026Article
- Primaquine-derived 5,6-orthoquinone concentrations in urine associated with CYP2D6 genotype-predicted phenotype and blood methemoglobin levels.Antimicrobial agents and chemotherapy · 2026Article
- Effect of higher dose primaquine for the radical cure ofThe Lancet regional health. Western Pacific · 2026Article
- Dissemination of EFFORT trial results in Indonesia: a stakeholder meeting report on tafenoquine and primaquine for radical cure of Plasmodium vivax.Malaria journal · 2026Article
- Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi.Parasites & vectors · 2026Article
- How CYP2D6 Polymorphism Modulates the Community-Wide Risk of Plasmodium vivax Infection: A Panel Study in Amazonian Brazil.The Journal of infectious diseases · 2025Article
- Article
- Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics.The Lancet. Infectious diseases · 2025Article
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.The Lancet. Infectious diseases · 2024Observational
- Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.Malaria journal · 2024Review
- Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure.Science advances · 2024Article
- A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways inbioRxiv : the preprint server for biology · 2024Article
- Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors.
James A Watson *Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam.ORCID 0000-0001-5524-0325
Robert J Commons *WorldWide Antimalarial Resistance Network, Oxford, United Kingdom.ORCID 0000-0002-3359-5632
Joel TarningCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-4566-4030
Julie A SimpsonCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-2660-2013
Alejandro Llanos CuentasUnit of Leishmaniasis and Malaria, Instituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
Marcus V G LacerdaFundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil.
Justin A GreenFormerly Senior Director, Global Health, GlaxoSmithKline, Brentford, United Kingdom.
Gavin C K W KohDepartment of Infectious Diseases, Northwick Park Hospital, Harrow, United Kingdom.
Cindy S ChuCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
François H NostenCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-7951-0745
Richard N PriceCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-2000-2874
Nicholas P J DayCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-2309-1171
Nicholas J WhiteCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-1897-1978
Funding
Wellcome Trust 093956/Z/10/CWellcome Trust 200909Wellcome Trust 200909/Z/16/ZWellcome Trust 223253/Z/21/Z
Abstract
Tafenoquine is a newly licensed antimalarial drug for the radical cure of
Indexed as
Malaria, VivaxHumansepidemiologyglobal healthhaemolysisinfectious diseasemicrobiologyPlasmodium vivaxradical curetafenoquine
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.